Recombinant Human vWF-A2 Protein, CF 50 UG

所属行业:生物试剂     有0人感兴趣

Recombinant Human vWF-A2 Protein, CF 50 UG信息二维码

微信扫码

 
基础投资电议
推荐指数
  • 区域全国
  • 留言暂无
  • 浏览0
  • 更新2024-07-25 20:36
  • 到期长期有效






更多>我还有产品
3-Amino-5-methoxycarbonylphenylboronic acid, pinacol ester  1 g 2,3-Dichloro-6-(trifluoromethyl)benzyl bromide  1 g 1-(4-Fluorophenyl)-5-methoxycarbonyl-2(1H)-pyridinone  1 g N,N-Diethyl-cyclohexane-1,4-diamine  1 g N-Methyl-DL-leucine hydrochloride  5 g N-(2-Chloroethyl) 3-boronobenzamide  5 g

产品介绍

    基本参数

    详细说明

    • Purity
      >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
    • Endotoxin Level
      <1.0 EU per 1 μg of the protein by the LAL method.
    • Activity
      Measured by its ability to be used as a protein substrate for ADAMTS13. >50% of rhvWF-A2 is cleaved as measured under the described conditions. See Activity Assay Protocol on www.RnDSystems.com
    • Source
      E. coli-derived Asp1498-Val1665, with an N-terminal Met and 6-His tag
    • Accession #
    • N-terminal Sequence
      Analysis
      Met
    • Predicted Molecular Mass
      20 kDa
    • SDS-PAGE
      18 kDa, reducing conditions
    2764-WF
     
    Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl and Glycerol.
    Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
    Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    • 6 months from date of receipt, -20 to -70 °C as supplied.
    • 3 months, -20 to -70 °C under sterile conditions after opening.
    Assay Procedure
    Materials
    • Assay Buffer: 50 mM Tris, 2 mM CaCl2, 0.01% (w/v) Brij-35, pH 8.5
    • Recombinant Human ADAMTS13 (rhADAMTS13) (Catalog # )
    • Recombinant Human vWF‑A2 (rhvWF‑A2) (Catalog # 2764-WF)
    • SDS-PAGE/Silverstain Reagents or equivalent
    1. Dilute rhvWF-A2 to 200 µg/mL in Assay Buffer.
    2. Dilute rhADAMTS13 to 20 µg/mL in Assay Buffer.
    3. Mix 25 µL of 200 µg/mL rhvWF-A2 with 25 µL of diluted rhADAMTS13. Prepare two Blanks by mixing 25 µL of 200 µg/mL rhvWF-A2 with 25 µL of Assay Buffer. 
    4. Incubate the mixture for 2 hours at 37 °C. Incubate one blank at 37 °C for 2 hours while keeping the other Blank at -20 °C.
    5. Stop the reaction by adding 15 µL of the reaction mixture to 15 µL of SDS-PAGE sample buffer. Also combine 15 µL of the blanks with 15 µL SDS-PAGE sample buffer.
    6. Analyze the cleavage by SDS PAGE (Load 20 µL per lane) followed by silver staining (1 µg rhvWF-A2 per lane).
    7. The cleavage products can also be analyzed by Western blot, loading 0.1 µg/lane of rhvWF-A2 and using one of R&D Systems antibodies ( or ).
    Per Reaction:
    • rhADAMTS13: 10 µg/mL (0.5 µg)
    • rhvWF-A2: 100 µg/mL (5 µg)
    Background: vWF-A2

    von Willebrand Factor (vWF) is a large, multimeric glycoprotein made by endothelial cells and megakaryocytes. The pre-pro-vWF protein contains 2813 amino acids (aa), which consists of 22 aa signal peptide, 741 aa propeptide and mature vWF monomer of 2050 aa (1‑4). The pro-vWF undergoes dimerization in the endoplasmic reticulum (ER) through C-terminal “cysteine-knot” (CK) domain. The pro-vWF dimmers are transported to Golgi and form multimers by forming disulfide bond in amino‑terminal region of the mature form. The proteolytic processing of pro-region also occurs in Golgi. The matured vWF is stored in Weibel-Pallade bodies in endothelial cells and granules in megakaryocytes and platelets. The unusually-large vWF (ulvWF) multimers released from cells are very efficient in binding to platelets to form thrombus. The population of these highly active ulvWF multimers is controlled by a specific protease, ADAMTS13, which cleaves between residues Tyr1605 and Met1606 in the A2 domain of vWF. In the plasma, vWF appears as a series of large and intermediate multimers with molecular masses from several thousand to 500 kDa. vWF also performs hemostatic functions (3‑5). In a high shear-stressed environment, vWF undergoes conformational change to expose a binding site for glycoprotein Ib alpha. As a result, vWF facilitates aggregation of platelets. In addition to platelet binding, vWF binds coagulation factor VIII to increase the lifetime of FVIII in plasma. The purified recombinant human vWF-A2 contains the A2 domain of vWF.

    • References:
      1. Sadler, J. E. (1998) Annu. Rev. Biochem. 67:395.
      2. Ruggeri, Z. M. (2003) Cur. Opin. Hemat. 10:142.
      3. Michiels, J. J. et al. (2006) Clin. Appl. Thromb. Hemost. 12:397.
      4. Groot, E. et al. (2007) Cur. Opin. Hemat. 14:284.
      5. Lenting, P. J. et al. (2007) J. Thromb. Haemos. 5:1353.
    • Long Name:
      von Willebrand Factor A2 Domain
    • Entrez Gene IDs:
      7450 (Human); 22371 (Mouse); 116669 (Rat)
    • Alternate Names:
      F8VWF; VWD; VWF von Willebrand factor; VWF; vWFA2; vWF-A2
    举报收藏 0评论 0
 
热门项目排行榜快速发布信息
14-(2-碘代乙基)辛基苯 9
2高温波导测试
3格列美脲 98%+ RG  5g
44-溴-3,5-二氯三氟甲苯
5二次谐波
6远红外云试剂
生物试剂排行榜快速发布信息
1Recombinant Human LILR
2Recombinant Human CD47
3Recombinant Human FGF
4203mm具砂板闪式层析柱,
5pUCm-T 载体 5UG
65ml Protein A40 Plus亲
最新加入项目快速发布信息
1质粒大量抽提试剂盒(通
2实验试剂
3产品标题产品标题产品标
4实验试剂
53-Amino-5-methoxycarbo
6N,N-Diethyl-cyclohexan

猜你喜欢产品快速发布信息

相关栏目

还没找到您需要的生物试剂产品?立即发布您的求购意向,让生物试剂公司主动与您联系!

立即发布项目意向

免责声明

本网页所展示的有关【Recombinant Human vWF-A2 Protein, CF 50 UG_生物试剂_云试剂自营四店】的信息/图片/参数等由云试剂的会员【云试剂自营四店】提供,由云试剂会员【云试剂自营四店】自行对信息/图片/参数等的真实性、准确性和合法性负责,本平台(本网站)仅提供展示服务,请谨慎交易,因交易而产生的法律关系及法律纠纷由您自行协商解决,本平台(本网站)对此不承担任何责任。您在本网页可以浏览【Recombinant Human vWF-A2 Protein, CF 50 UG_生物试剂_云试剂自营四店】有关的信息/图片/价格等及提供【Recombinant Human vWF-A2 Protein, CF 50 UG_生物试剂_云试剂自营四店】的商家公司简介、联系方式等信息。

联系方式

在您的合法权益受到侵害时,欢迎您向www@yunshiji.cn邮箱发送邮件,或者进入《网站意见反馈》了解投诉处理流程,我们将竭诚为您服务,感谢您对云试剂的关注与支持!

按排行字母分类找加盟项目:

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z